Clofazimine Pharma, Clofazimine manufacturer India, Clofazimine Supplier, Clofazimine Exporter, Clofazimine 100mg Capsules Pharmaceuticals Clofazimine Medicines
Clofazimine Pharma, Clofazimine
manufacturer India, Clofazimine Supplier, Clofazimine Exporter, Clofazimine
100mg Capsules Pharmaceuticals Clofazimine Medicines Manufacturer Clofazimine,
Clofazimine manufacturer India, gynace product, Clofazimine , Clofazimine anti
ulcer product, Clofazimine, Clofazimine pharmaceutical generic, Clofazimine
pharmaceutical drug, Clofazimine medical, Clofazimine pharma healthcare, Clofazimine contract
manufacturing, Clofazimine pharma, Clofazimine generic pharma, Clofazimine
pharma pharmaceutical Clofazimine products, Clofazimine Pharmaceutical gmp formulations manufacturer,
Clofazimine pharmaceutical Clofazimine exporter from India, pharma Clofazimine
medicine, api, generic medicine Clofazimine, Clofazimine products, Clofazimine
caps, Clofazimine tablets, Clofazimine API, Clofazimine , Clofazimine supplier,
Clofazimine who gmp, Clofazimine US FDA, Clofazimine WHO, UKMHRA Approved
Clofazimine Capsules BP 100mg Taj Pharma
Clofazimine Capsules BP 50mg Taj Pharma
Clofazimine Capsules BP 100mg Taj Pharma
DESCRIPTION
Clofazimine is an antimycobacterial available as soft gelatin capsules for oral administration. Each capsule contains 50 mg of micronized clofazimine suspended in an oil-wax base. Clofazimine is a substituted iminophenazine bright-red dye. Its chemical name is 3-(p-chloroanilino)-10-(p-chlorophenyl)-2, 10-dihydro-2-isopropyliminophenazine.
Clofazimine is a reddish-brown powder. It is readily soluble in benzene; soluble in chloroform; poorly soluble in acetone and in ethyl acetate; sparingly soluble in methanol and in ethanol; and virtually insoluble in water. Its molecular weight is 473.4. Its molecular formula is C27H22Cl2N4.
Inactive Ingredients In Capsules
Beeswax, butylated hydroxytoluene, citric acid, ethyl vanillin, gelatin, glycerin, iron oxide, lecithin, p-methoxy acetophenone, parabens, plant oils, propylene glycol.
Capsule Shells Contain
ethyl parahydroxybenzoate sodium, propyl parahydroxybenzoate sodium, ethylvanillin, gelatin, glycerol 85%, black iron oxide, red iron oxide, p-methoxy acetophenone.
Categories: Antileprotic, Export Only, Generic Brands, Tablets Capsules
Clofazimine 50mg
Excipients q.s
in a soft gelatin capsule.
The capsules are brown and spherical.
b) Each Clofazimine capsule 100mg contains:
Clofazimine 100mg
Excipients q.s
in a soft gelatin capsule.
The capsules are brown and spherical.
Storage And Handling
Do not store above 25°C (77°F). Protect from moisture.
Dispense in tight container (USP).
Skin: Pigmentation from pink to brownish-black in 75% to 100% of the
patients within a few weeks of treatment; ichthyosis and dryness (8% to
28%); rash and pruritus (1% to 5%).
Gastrointestinal: Abdominal and epigastric pain, diarrhea, nausea, vomiting, gastrointestinal intolerance (40%-to-50%).
Ocular: Conjunctival and corneal pigmentation due to clofazimine crystal deposits; dryness; burning; itching; irritation.
Other: Discoloration of urine, feces, sputum, sweat; elevated blood sugar; elevated erythrocyte sedimentation rate (ESR).
Gastrointestinal: Bowel obstruction, gastrointestinal bleeding, anorexia, constipation, weight loss, hepatitis, jaundice, eosinophilic enteritis, enlarged liver.
Ocular: Diminished vision, maculopathy (bull’s eye retinopathy).
Nervous: Dizziness, drowsiness, fatigue, headache, giddiness, neuralgia, taste disorder.
Psychiatric: Depression and suicide secondary to skin discoloration.
Laboratory: Elevated levels of albumin, serum bilirubin, and aspartate aminotransferase (AST); eosinophilia; hypokalemia.
Other: Splenic infarction, thromboembolis,
anemia, cystitis, bone pain, edema, fever, lymphadenopathy, vascular pain.
Clofazimine may accumulate in various organs as crystals, including
the mesenteric lymph nodes and histiocytes at the lamina propria of the
intestinal mucosa, spleen and liver. Deposition in the intestinal mucosa
may lead to intestinal obstruction that may necessitate
exploratory laparotomy. Splenic infarction, gastrointestinal bleeding,
and death have been reported. If a patient complains of pain in the
abdomen, nausea, vomiting, or diarrhea, initiate appropriate medical
investigations and reduce the daily dose of Clofazimine, or increase the
dosing interval or discontinue the drug. Doses of Clofazimine of more
than 100 mg daily should be given for as short a period as possible
(less than 3 months) and only under close medical supervision.
QT prolongation has also been reported in patients who were receiving Clofazimine with bedaquiline at the recommended dosage regimen for each drug. Monitor ECGs if Clofazimine is coadministered to patients receiving bedaquiline, and discontinue Clofazimine if clinically significant ventricular arrhythmia is noted or if the QTcF interval is 500 ms or greater. If syncope occurs, obtain an ECG to detect QT prolongation.
Clofazimine causes orange-pink to brownish-black discoloration of the
skin, as well as discoloration of the conjunctivae, tears, sweat,
sputum, urine and feces in 75-100% of patients. Advise patients that
skin discoloration is likely to occur and that it may take several
months or years to reverse after the conclusion of therapy.
Other skin reactions associated with Clofazimine therapy include ichthyosis, dry skin and pruritus.
Impaired female fertility (reduced number of offspring and lower proportion of implantations) was observed in one study in rats receiving Clofazimine (from 9 weeks before mating until weaning) at 50 mg/kg/day, equivalent to about 2.4 times the maximum recommended clinical dose. No non-clinical data on male fertility are available.
There are no data with Clofazimine use in pregnant women to inform associated risk. Retardation of fetal skull ossification, increased incidences of abortions and stillbirths, and impaired neonatal survival were observed in mice following prenatal exposure to Clofazimine at 25 mg/kg, equivalent to the 0.6 times maximum recommended human daily dose (200 mg), based on body surface area comparisons. Advise pregnant women of the potential risk to the fetus.
The background risk of major birth defects and miscarriage for the indicated population is unknown; however, in the U.S. general population, the estimated background risk of major birth defects is 2-4% and of miscarriage is 15-20% of clinically recognized pregnancies.
The skin of infants born to pregnant mothers who had received Clofazimine during pregnancy is pigmented at birth.
Limited data is available regarding the reversibility of discoloration. Based on previous observations, discoloration gradually faded over the first year.
There are no studies of Clofazimine use in pregnant women. Few cases of clofazimine use during pregnancy have been reported in the literature. These reports indicate that the skin of infants born to women who had received Clofazimine during pregnancy was deeply pigmented at birth. Clofazimine should be used during pregnancy only if the potential benefit justifies the risk to the fetus.
Animal Data
Embryofetal toxicity studies were conducted in rats, rabbits and
mice. In mice Clofazimine-induced embryotoxicity and fetotoxicity was
evident. Retardation of fetal skull ossification, increased incidences
of abortions and stillbirths, and impaired neonatal survival were
observed following prenatal exposure to Clofazimine at 25 mg/kg,
equivalent to the 0.6 times maximum recommended human daily dose [MRHD]
(200 mg), based on body surface area comparisons. The skin and fatty
tissue of offspring became discolored approximately 3 days after birth,
which was attributed to the presence of clofazimine in the maternal
milk. No developmental effects were observed in rat or rabbits orally
administered clofazimine during organogenesis at doses up to 50 mg/kg
and 15 mg/kg,(equivalent to about 2.4 and 1.5 times the MRHD of 200 mg
based on body surface area) respectively. These animal studies were
conducted according to the standards at the time of initial drug
approval (1986) and not under current regulatory standards.
The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Clofazimine and any potential adverse effects on the breastfed infant from Clofazimine or from the underlying maternal condition.
Advise males taking Clofazimine to use a condom during intercourse while on treatment and for at least 4 months after stopping treatment with Clofazimine.
Clinical studies of Clofazimine did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
No specific data are available on the treatment of overdosage with
Clofazimine. However, in case of overdose, the stomach should be emptied
by inducing vomiting or by gastric lavage, and supportive symptomatic
treatment should be employed.
Time to reach peak plasma concentration (median Tmax) of clofazimine decreases from 12 hours to 8 hours under fed conditions relative to the fasted state.
Clofazimine is highly lipophilic and tends to be deposited predominantly in fatty tissue and in cells of the reticuloendothelial system. It is taken up by macrophages throughout the body. In autopsies performed on leprosy patients who had received Clofazimine, clofazimine crystals were found predominantly in the mesenteric lymph nodes, adrenals, subcutaneous fat, liver, bile, gall bladder, spleen, small intestine, muscles, bones, and skin.
Clofazimine is bound to alpha-and beta-lipoproteins in serum, particularly the beta-lipoproteins, and the binding was saturable at plasma concentrations of approximately 10 mcg/mL. Binding to gamma-globulin and albumin was negligible.
After ingestion of a single 300 mg dose of Clofazimine, elimination
of unchanged clofazimine and its metabolites in a 24-hour urine
collection was negligible. Part of the ingested drug recovered from the
feces may represent excretion via the bile. A small amount is also
eliminated in the sputum, sebum, and sweat. The elimination half-life of
clofazimine following repeated oral doses of 50 or 100 mg Clofazimine
in leprosy patients was highly variable with estimates ranging from 6.5
to 160 days. The overall mean half-life of clofazimine in these leprosy
patients was approximately 25 days.
The mechanism of action for the antimycobacterial activity of clofazimine can be postulated through its membrane-directed activity including the bacterial respiratory chain and ion transporters. Intracellular redox cycling, involving oxidation of reduced clofazimine, leads to the generation of antimicrobial reactive oxygen species (ROS), superoxidehydrogen peroxide (H2O2). Secondly, interaction of clofazimine with membrane phospholipids results in the generation of antimicrobial lysophospholipids, which promote membrane dysfunction, resulting in interference with K+ uptake. Both mechanisms result in interference with cellular energy metabolism by disrupting ATP production. Anti-inflammatory activity of clofazimine is primarily through inhibition of T lymphocyte activation and proliferation. Clofazimine may indirectly interfere with the proliferation of T cells by promoting the release of ROS and E-series prostaglandins (PGs), especially PGE2 from neutrophils and monocytes.
Measurement of the minimum inhibitory concentration (MIC) of clofazimine against leprosy bacilli in vitro is not yet feasible.
PATIENT INFORMATION
TAJ PHARMACEUTICALS LTD.
Mumbai, India
Unit No. 214.Old Bake House,
Maharashtra chambers of Commerce Lane,
Fort, Mumbai – 400001
at: Gujarat, INDIA.
Customer Service and Product Inquiries:
1-800-TRY-FIRST (1-800-222-434 & 1-800-222-825)
Monday through Saturday 9:00 a.m. to 7:00 p.m. EST
E-mail: tajgroup@tajpharma.com
Clofazimine is an antibiotic used for the treatment of Mycobacterium
avium complex (MAC) infection. It may also be used to treat a number of
other conditions.
the recommended dose is 100 to 300mg daily. It should be given in combination with other antibiotics.
Clofazimine should be taken with food to avoid an upset stomach. You should drink a full glass of water with each dose of clofazimine.
Your dosage is:
. 50 mg capsule
. 100 mg capsule
Clofazimine may cause skin and eye dryness and itchiness. You should always use a good hydrating cream to avoid skin dryness. Also, your skin may become more sensitive to the sun and sunlamps. Please consult a doctor immediately if you develop a skin rash.
Discolouration (red – brownish black) of feces, lining of the eyelids, sputum,sweat, tears and urine commonly occurs. Usually, this adverse effect does not require medical attention. However, if you wear contact lenses, you might consider wearing glasses instead to prevent discolouration of your contact lenses. Many people develop nausea, vomiting, stomach upset and diarrhea while receiving clofazimine. If these effects are bothersome, please inform your doctor or pharmacist.
Rarely, clofazimine may cause liver damage. Increases in liver enzymes accompanied with severe nausea,
vomiting, abdominal pain, bloody or black tarry stools, and yellow eyes or skin may occur. Please notify a doctor immediately if you notice these symptoms. Your doctor will check your liver enzymes when you come to the clinic for blood tests.
It is important that you keep your doctor appointments and come for your laboratory tests so that your progress can be followed.
Before starting clofazimine, please inform your doctor and pharmacist
if you have ever had an allergic reaction to this drug in the past.
As this drug may cause some people to become dizzy, drowsy or less alert than normal, you should make sure you know how you react to this drug before you drive, use machinery or do anything else
that could be dangerous if you are dizzy or are not alert.
Clofazimine can make your skin more sensitive to sunlight or sunlamps than usual. Therefore, wear protective clothing and use a sunscreen with at least an SPF of 15 whenever you are exposed to the sun. You should avoid sunlamps. Ask your pharmacist to help you select a sunscreen that protects against drug-sun reactions.
Clofazimine may interfere with certain drugs. In particular, phenytoin and fosphenytoin. Inform your doctor and pharmacist of all prescribed and nonprescribed drugs you are taking. As well, you should inform them of natural products you are taking. If you wish to start a new drug or natural product,
please consult with your pharmacist before doing so.
The safety of clofazimine during pregnancy has not been established. Please inform your doctor if you are
pregnant. Clofazimine should only be given to pregnant women if the potential benefits of treatment outweigh the potential risks to the child.
Breastfeeding is NOT recommended while you are receiving clofazimine.
Ensure that the drug has not expired by checking the expiry date (“EXP”) shown on the outside of the package.
Do not store where there is heat and moisture (for example, in the bathroom or near the stove) as the drug may become less active.
If you have any questions or concerns about this drug or if you are experiencing adverse effects, please discuss them with your pharmacist, doctor or nurse.
7. Manufactured in India by:
TAJ PHARMACEUTICALS LTD.
Mumbai, India
Unit No. 214.Old Bake House,
Maharashtra chambers of Commerce Lane,
Fort, Mumbai – 400001
at: Gujarat, INDIA.
Customer Service and Product Inquiries:
1-800-TRY-FIRST (1-800-222-434 & 1-800-222-825)
Monday through Saturday 9:00 a.m. to 7:00 p.m. EST
E-mail: tajgroup@tajpharma.com
Clofazimine Capsules BP 100mg Taj Pharma
 |
Clofazimine Capsules BP 100mg Taj Pharma |
Clofazimine is an antimycobacterial available as soft gelatin capsules for oral administration. Each capsule contains 50 mg of micronized clofazimine suspended in an oil-wax base. Clofazimine is a substituted iminophenazine bright-red dye. Its chemical name is 3-(p-chloroanilino)-10-(p-chlorophenyl)-2, 10-dihydro-2-isopropyliminophenazine.
Clofazimine is a reddish-brown powder. It is readily soluble in benzene; soluble in chloroform; poorly soluble in acetone and in ethyl acetate; sparingly soluble in methanol and in ethanol; and virtually insoluble in water. Its molecular weight is 473.4. Its molecular formula is C27H22Cl2N4.
Inactive Ingredients In Capsules
Beeswax, butylated hydroxytoluene, citric acid, ethyl vanillin, gelatin, glycerin, iron oxide, lecithin, p-methoxy acetophenone, parabens, plant oils, propylene glycol.
Capsule Shells Contain
ethyl parahydroxybenzoate sodium, propyl parahydroxybenzoate sodium, ethylvanillin, gelatin, glycerol 85%, black iron oxide, red iron oxide, p-methoxy acetophenone.
INDICATIONS
Lepromatous Leprosy
Clofazimine is indicated in combination with other antileprosy drugs for the treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy, and lepromatous leprosy complicated by erythema nodosum leprosum.Usage
To prevent the development of drug-resistance, Clofazimine should be used only as a part of combination therapy for initial treatment of lepromatous (multibacillary) leprosy [see DOSAGE AND ADMINISTRATION].Categories: Antileprotic, Export Only, Generic Brands, Tablets Capsules
DOSAGE AND ADMINISTRATION
Dosage
Dapsone-Sensitive Lepromatous (multibacillary) Leprosy
Administer 100 mg Clofazimine daily with meals in combination with two other antileprosy drugs for at least 2 years and if possible, until negative skin smears are obtained, followed by monotherapy with an appropriate antileprosy drug.
Dapsone-Resistant Lepromatous Leprosy
Administer 100 mg Clofazimine daily with meals in combination with one or more other antileprosy drugs for 3 years, followed by monotherapy with 100 mg of Clofazimine daily.Lepromatous Leprosy Complicated By Erythema Nodosum Leprosum Reactions
Administer Clofazimine at 100 mg to 200 mg daily, in conjunction with baseline antileprosy treatment and steroids as clinically indicated. If Clofazimine is administered at 200 mg dose, taper to 100 mg as soon as possible after the erythema nodosum reaction is controlled. Doses of Clofazimine of more than 100 mg daily should be given for as short a period as possible and only under close medical supervision [see WARNINGS AND PRECAUTIONS].Important Pre-test Prior To Administration
Sexually-active females of reproductive potential should have a pregnancy test prior to Clofazimine administration [see Use In Specific Populations].HOW SUPPLIED
Dosage Forms And Strengths
a) Each Clofazimine capsule 50mg contains:Clofazimine 50mg
Excipients q.s
in a soft gelatin capsule.
The capsules are brown and spherical.
b) Each Clofazimine capsule 100mg contains:
Clofazimine 100mg
Excipients q.s
in a soft gelatin capsule.
The capsules are brown and spherical.
Storage And Handling
Do not store above 25°C (77°F). Protect from moisture.
Dispense in tight container (USP).
SIDE EFFECTS
The following serious adverse reactions are discussed in greater detail in other sections of the labeling:- Abdominal Obstruction and Gastrointestinal Adverse Reactions [seeWARNINGS AND PRECAUTIONS]
- QT Prolongation [see WARNINGS AND PRECAUTIONS]
- Skin and Body Fluid Discoloration and Other Skin Reactions [seeWARNINGS AND PRECAUTIONS]
- Psychological Effects of Skin Discoloration [see WARNINGS AND PRECAUTIONS]
Adverse Reactions Occurring In More Than 1% of Patients
Skin: Pigmentation from pink to brownish-black in 75% to 100% of the
patients within a few weeks of treatment; ichthyosis and dryness (8% to
28%); rash and pruritus (1% to 5%).Gastrointestinal: Abdominal and epigastric pain, diarrhea, nausea, vomiting, gastrointestinal intolerance (40%-to-50%).
Ocular: Conjunctival and corneal pigmentation due to clofazimine crystal deposits; dryness; burning; itching; irritation.
Other: Discoloration of urine, feces, sputum, sweat; elevated blood sugar; elevated erythrocyte sedimentation rate (ESR).
Adverse Reactions Occurring In Less Than 1% of Patients
Skin: Phototoxicity, erythroderma, acneiform eruptions, monilial cheilosis.Gastrointestinal: Bowel obstruction, gastrointestinal bleeding, anorexia, constipation, weight loss, hepatitis, jaundice, eosinophilic enteritis, enlarged liver.
Ocular: Diminished vision, maculopathy (bull’s eye retinopathy).
Nervous: Dizziness, drowsiness, fatigue, headache, giddiness, neuralgia, taste disorder.
Psychiatric: Depression and suicide secondary to skin discoloration.
Laboratory: Elevated levels of albumin, serum bilirubin, and aspartate aminotransferase (AST); eosinophilia; hypokalemia.
Other: Splenic infarction, thromboembolis,
anemia, cystitis, bone pain, edema, fever, lymphadenopathy, vascular pain.
DRUG INTERACTIONS
No Information providedWARNINGS
Included as part of the PRECAUTIONS section.PRECAUTIONS
Abdominal Obstruction And Other Gastrointestinal Adverse Reactions
QT prolongation
Cases of Torsades de Pointes with QT prolongation have been reported in patients receiving dosage regimens containing higher than 100 mg daily dose of Clofazimine or in combination with QT prolonging medications. For QT prolongation and Torsades de Pointes cases, the patient must remain under medical surveillance. In all these patients, monitor electrocardiograms (ECGs) for QT prolongation and cardiac rhythm disturbances [see DOSAGE AND ADMINISTRATION].QT prolongation has also been reported in patients who were receiving Clofazimine with bedaquiline at the recommended dosage regimen for each drug. Monitor ECGs if Clofazimine is coadministered to patients receiving bedaquiline, and discontinue Clofazimine if clinically significant ventricular arrhythmia is noted or if the QTcF interval is 500 ms or greater. If syncope occurs, obtain an ECG to detect QT prolongation.
Skin And Body Fluid Discoloration And Other Skin Reactions
Clofazimine causes orange-pink to brownish-black discoloration of the
skin, as well as discoloration of the conjunctivae, tears, sweat,
sputum, urine and feces in 75-100% of patients. Advise patients that
skin discoloration is likely to occur and that it may take several
months or years to reverse after the conclusion of therapy.Other skin reactions associated with Clofazimine therapy include ichthyosis, dry skin and pruritus.
Psychological Effects Of Skin Discoloration
Skin discoloration due to Clofazimine therapy has been reported to result in depression and suicide. Advise patients regarding skin discoloration and monitor for depression or suicidal ideation during Clofazimine therapy.Nonclinical Toxicology
Carcinogenesis, Mutagenesis, And Impairment Of Fertility
Long-term carcinogenicity studies in animals have not been conducted with Clofazimine. Results of mutagenicity studies (Ames test) were negative. There is some evidence of clastogenic potential in mice.Impaired female fertility (reduced number of offspring and lower proportion of implantations) was observed in one study in rats receiving Clofazimine (from 9 weeks before mating until weaning) at 50 mg/kg/day, equivalent to about 2.4 times the maximum recommended clinical dose. No non-clinical data on male fertility are available.
Use In Specific Populations
Pregnancy
Risk Summary
There are no data with Clofazimine use in pregnant women to inform associated risk. Retardation of fetal skull ossification, increased incidences of abortions and stillbirths, and impaired neonatal survival were observed in mice following prenatal exposure to Clofazimine at 25 mg/kg, equivalent to the 0.6 times maximum recommended human daily dose (200 mg), based on body surface area comparisons. Advise pregnant women of the potential risk to the fetus.
The background risk of major birth defects and miscarriage for the indicated population is unknown; however, in the U.S. general population, the estimated background risk of major birth defects is 2-4% and of miscarriage is 15-20% of clinically recognized pregnancies.
Clinical Considerations
Fetal/Neonatal Adverse ReactionsThe skin of infants born to pregnant mothers who had received Clofazimine during pregnancy is pigmented at birth.
Limited data is available regarding the reversibility of discoloration. Based on previous observations, discoloration gradually faded over the first year.
Data
Human DataThere are no studies of Clofazimine use in pregnant women. Few cases of clofazimine use during pregnancy have been reported in the literature. These reports indicate that the skin of infants born to women who had received Clofazimine during pregnancy was deeply pigmented at birth. Clofazimine should be used during pregnancy only if the potential benefit justifies the risk to the fetus.
Animal Data
Lactation
Risk summary
Clofazimine is excreted in human milk. Skin discoloration has been observed in breast fed neonates of mothers receiving clofazimine.The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Clofazimine and any potential adverse effects on the breastfed infant from Clofazimine or from the underlying maternal condition.
Females And Males Of Reproductive Potential
Pregnancy Testing
Sexually-active females of reproductive potential should have a pregnancy test prior to starting treatment with Clofazimine.Contraception
Animal studies have shown Clofazimine to be harmful to the developing fetus. Advise sexually active females of reproductive potential to use effective contraception (methods that result in less than 1 % pregnancy rates) when using Clofazimine during treatment and for at least 4 months after stopping treatment with Clofazimine.Advise males taking Clofazimine to use a condom during intercourse while on treatment and for at least 4 months after stopping treatment with Clofazimine.
Infertility
Impaired female fertility (reduced number of offspring and lower proportion of implantations) was observed in one study in rats receiving Clofazimine [see Nonclinical Toxicology]. There are no non-clinical data on male fertility.Pediatric Use
Safety and effectiveness of Clofazimine in pediatric patients have not been established.Geriatric Use
Clinical studies of Clofazimine did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Patients with HIV Co-infection
Response to treatment, including treatment of erythema nodosum leprosum reactions, is not altered in HIV-positive and immunocompromised leprosy patients. Dose adjustments of Clofazimine are not required in these patients.OVERDOSE
No specific data are available on the treatment of overdosage with
Clofazimine. However, in case of overdose, the stomach should be emptied
by inducing vomiting or by gastric lavage, and supportive symptomatic
treatment should be employed.CONTRAINDICATIONS
Clofazimine is contraindicated in patients with known hypersensitivity to clofazimine or any of the excipients of Clofazimine.CLINICAL PHARMACOLOGY
Mechanism Of Action
Clofazimine is an antimycobacterial drug [see Microbiology].Pharmacokinetics
Absorption
Clofazimine has a variable absorption rate in leprosy patients, ranging from 45% to 62% after oral administration of Clofazimine. The average serum concentrations of clofazimine in leprosy patients treated with Clofazimine 100 mg and 300 mg daily were 0.7 mcg/mL and 1 mcg/mL, respectively.Time to reach peak plasma concentration (median Tmax) of clofazimine decreases from 12 hours to 8 hours under fed conditions relative to the fasted state.
Distribution
Clofazimine is highly lipophilic and tends to be deposited predominantly in fatty tissue and in cells of the reticuloendothelial system. It is taken up by macrophages throughout the body. In autopsies performed on leprosy patients who had received Clofazimine, clofazimine crystals were found predominantly in the mesenteric lymph nodes, adrenals, subcutaneous fat, liver, bile, gall bladder, spleen, small intestine, muscles, bones, and skin.
Clofazimine is bound to alpha-and beta-lipoproteins in serum, particularly the beta-lipoproteins, and the binding was saturable at plasma concentrations of approximately 10 mcg/mL. Binding to gamma-globulin and albumin was negligible.
Metabolism
Three clofazimine metabolites were found in urine following repeated oral doses of Clofazimine. Information on the metabolism of clofazimine is limited.Elimination
Microbiology
Mechanism Of Action
Clofazimine exerts a slow bactericidal effect on Mycobacterium leprae (Hansen’s bacillus). Clofazimine inhibits mycobacterial growth and binds preferentially to mycobacterial DNA. Clofazimine also exerts anti-inflammatory properties in treating erythema nodosum leprosum reactions. However, its precise mechanisms of action are unknown.The mechanism of action for the antimycobacterial activity of clofazimine can be postulated through its membrane-directed activity including the bacterial respiratory chain and ion transporters. Intracellular redox cycling, involving oxidation of reduced clofazimine, leads to the generation of antimicrobial reactive oxygen species (ROS), superoxidehydrogen peroxide (H2O2). Secondly, interaction of clofazimine with membrane phospholipids results in the generation of antimicrobial lysophospholipids, which promote membrane dysfunction, resulting in interference with K+ uptake. Both mechanisms result in interference with cellular energy metabolism by disrupting ATP production. Anti-inflammatory activity of clofazimine is primarily through inhibition of T lymphocyte activation and proliferation. Clofazimine may indirectly interfere with the proliferation of T cells by promoting the release of ROS and E-series prostaglandins (PGs), especially PGE2 from neutrophils and monocytes.
Measurement of the minimum inhibitory concentration (MIC) of clofazimine against leprosy bacilli in vitro is not yet feasible.
Cross-Resistance
Clofazimine does not show cross-resistance with dapsone or rifampin.PATIENT INFORMATION
- Inform patients to take Clofazimine with meals.
- Inform patients to report abdominal pain or other gastrointestinal symptoms, such as nausea or vomiting, to their healthcare provider.
- Inform patients that Clofazimine frequently causes a red to brownish-black discoloration of the skin as well as discoloration of the conjunctivae, tears, sweat, sputum, urine, and feces. Advise patients that skin discoloration may take several months or years to resolve after the conclusion of therapy with Clofazimine.
- Inform patients that skin discoloration may result in psychological effects and advise them to report any symptoms of depression or suicidal ideation.
- Advise females of reproductive potential to use effective contraception while taking Clofazimine and for at least 4 months after stopping treatment with Clofazimine. It is also recommended that they have a pregnancy test prior to starting treatment with Clofazimine.
- Advise males taking LAMRENE to use a condom during intercourse while taking Clofazimine and for at least 4 months after stopping treatment.
- Inform patients of the importance of compliance with the prescribed drug regimen in order to prevent drug resistance. Irregularity in administration of medication and poor compliance can lead to delayed and incomplete cure, and could result in infecting other people. Poor compliance can result in disease progression and ultimately result in the development of disabilities and deformities. Whenever possible, ensure that non-compliant patients receive adequate assessment, health education and supervised treatment.
- Instruct patients on the recognition of signs and symptoms of inflammatory reactions and relapses during and following completion of treatment, and instruct them regarding the importance of immediately reporting the earliest manifestations of these signs to their healthcare provider.
TAJ PHARMACEUTICALS LTD.
Mumbai, India
Unit No. 214.Old Bake House,
Maharashtra chambers of Commerce Lane,
Fort, Mumbai – 400001
at: Gujarat, INDIA.
Customer Service and Product Inquiries:
1-800-TRY-FIRST (1-800-222-434 & 1-800-222-825)
Monday through Saturday 9:00 a.m. to 7:00 p.m. EST
E-mail: tajgroup@tajpharma.com
Clofazimine Capsules BP 100mg Taj Pharma
- WHY is this drug prescribed?
- HOW should this drug be taken?
the recommended dose is 100 to 300mg daily. It should be given in combination with other antibiotics.
Clofazimine should be taken with food to avoid an upset stomach. You should drink a full glass of water with each dose of clofazimine.
Your dosage is:
. 50 mg capsule
. 100 mg capsule
- What should you do if you FORGET a dose?
- What ADVERSE EFFECTS can this drug cause? What should you do about them?
Clofazimine may cause skin and eye dryness and itchiness. You should always use a good hydrating cream to avoid skin dryness. Also, your skin may become more sensitive to the sun and sunlamps. Please consult a doctor immediately if you develop a skin rash.
Discolouration (red – brownish black) of feces, lining of the eyelids, sputum,sweat, tears and urine commonly occurs. Usually, this adverse effect does not require medical attention. However, if you wear contact lenses, you might consider wearing glasses instead to prevent discolouration of your contact lenses. Many people develop nausea, vomiting, stomach upset and diarrhea while receiving clofazimine. If these effects are bothersome, please inform your doctor or pharmacist.
Rarely, clofazimine may cause liver damage. Increases in liver enzymes accompanied with severe nausea,
vomiting, abdominal pain, bloody or black tarry stools, and yellow eyes or skin may occur. Please notify a doctor immediately if you notice these symptoms. Your doctor will check your liver enzymes when you come to the clinic for blood tests.
It is important that you keep your doctor appointments and come for your laboratory tests so that your progress can be followed.
- What other PRECAUTIONS should you follow while using this drug?
As this drug may cause some people to become dizzy, drowsy or less alert than normal, you should make sure you know how you react to this drug before you drive, use machinery or do anything else
that could be dangerous if you are dizzy or are not alert.
Clofazimine can make your skin more sensitive to sunlight or sunlamps than usual. Therefore, wear protective clothing and use a sunscreen with at least an SPF of 15 whenever you are exposed to the sun. You should avoid sunlamps. Ask your pharmacist to help you select a sunscreen that protects against drug-sun reactions.
Clofazimine may interfere with certain drugs. In particular, phenytoin and fosphenytoin. Inform your doctor and pharmacist of all prescribed and nonprescribed drugs you are taking. As well, you should inform them of natural products you are taking. If you wish to start a new drug or natural product,
please consult with your pharmacist before doing so.
The safety of clofazimine during pregnancy has not been established. Please inform your doctor if you are
pregnant. Clofazimine should only be given to pregnant women if the potential benefits of treatment outweigh the potential risks to the child.
Breastfeeding is NOT recommended while you are receiving clofazimine.
- How should this drug be STORED?
Ensure that the drug has not expired by checking the expiry date (“EXP”) shown on the outside of the package.
Do not store where there is heat and moisture (for example, in the bathroom or near the stove) as the drug may become less active.
If you have any questions or concerns about this drug or if you are experiencing adverse effects, please discuss them with your pharmacist, doctor or nurse.
7. Manufactured in India by:
TAJ PHARMACEUTICALS LTD.
Mumbai, India
Unit No. 214.Old Bake House,
Maharashtra chambers of Commerce Lane,
Fort, Mumbai – 400001
at: Gujarat, INDIA.
Customer Service and Product Inquiries:
1-800-TRY-FIRST (1-800-222-434 & 1-800-222-825)
Monday through Saturday 9:00 a.m. to 7:00 p.m. EST
E-mail: tajgroup@tajpharma.com
Clofazimine Capsules 100mg: Uses, Side Effects, Interactions, Pictures, Warnings, contraindication
Clofazimine Capsules 100mg
Clofazimine Capsules 100mg
DESCRIPTION
Clofazimine is an antimycobacterial available as soft gelatin capsules for oral administration. Each capsule contains 50 mg of micronized clofazimine suspended in an oil-wax base. Clofazimine is a substituted iminophenazine bright-red dye. Its chemical name is 3-(p-chloroanilino)-10-(p-chlorophenyl)-2, 10-dihydro-2-isopropyliminophenazine.
Clofazimine Capsule 
Clofazimine Capsule 
Clofazimine Capsule 
Clofazimine Capsule 
Clofazimine Capsule 
Clofazimine Capsule 
Clofazimine Capsule 
Clofazimine Capsule 
Clofazimine Capsule 
Clofazimine Capsule 
Clofazimine Capsule 
Clofazimine Capsule 
Clofazimine Capsule 
Clofazimine Capsule
Inactive Ingredients In Capsules
Beeswax, butylated hydroxytoluene, citric acid, ethyl vanillin, gelatin, glycerin, iron oxide, lecithin, p-methoxy acetophenone, parabens, plant oils, propylene glycol.
Capsule Shells Contain
ethyl parahydroxybenzoate sodium, propyl parahydroxybenzoate sodium, ethylvanillin, gelatin, glycerol 85%, black iron oxide, red iron oxide, p-methoxy acetophenone.
INDICATIONS
Lepromatous Leprosy
Clofazimine is indicated in combination with other antileprosy drugs for the treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy, and lepromatous leprosy complicated by erythema nodosum leprosum.Usage
To prevent the development of drug-resistance, Clofazimine should be used only as a part of combination therapy for initial treatment of lepromatous (multibacillary) leprosyDOSAGE AND ADMINISTRATION
Dosage
Dapsone-Sensitive Lepromatous (multibacillary) Leprosy
Administer 100 mg Clofazimine daily with meals in combination with two other antileprosy drugs for at least 2 years and if possible, until negative skin smears are obtained, followed by monotherapy with an appropriate antileprosy drug.Dapsone-Resistant Lepromatous Leprosy
Administer 100 mg Clofazimine daily with meals in combination with one or more other antileprosy drugs for 3 years, followed by monotherapy with 100 mg of Clofazimine daily.Lepromatous Leprosy Complicated By Erythema Nodosum Leprosum Reactions
Administer Clofazimine at 100 mg to 200 mg daily, in conjunction with baseline antileprosy treatment and steroids as clinically indicated. If Clofazimine is administered at 200 mg dose, taper to 100 mg as soon as possible after the erythema nodosum reaction is controlled. Doses of Clofazimine of more than 100 mg daily should be given for as short a period as possible and only under close medical supervision [see WARNINGS AND PRECAUTIONS].Important Pre-test Prior To Administration
Sexually-active females of reproductive potential should have a pregnancy test prior to Clofazimine administration [see Use In Specific Populations].HOW SUPPLIED
Dosage Forms And Strengths
a) Each Clofazimine capsule 50mg contains:Clofazimine 50mg
Excipients q.s.
in a soft gelatin capsule.
The capsules are brown and spherical.
b) Each Clofazimine capsule 100mg contains:
Clofazimine 100mg
Excipients q.s.
in a soft gelatin capsule.
The capsules are brown and spherical.
Bottles of 100
Storage And Handling
Do not store above 25°C (77°F). Protect from moisture.
Dispense in a tight container (USP).
SIDE EFFECTS
The following serious adverse reactions are discussed in greater detail in other sections of the labelling:- Abdominal Obstruction and Gastrointestinal Adverse Reactions [seeWARNINGS AND PRECAUTIONS]
- QT Prolongation [see WARNINGS AND PRECAUTIONS]
- Skin and Body Fluid Discoloration and Other Skin Reactions [seeWARNINGS AND PRECAUTIONS]
- Psychological Effects of Skin Discoloration [see WARNINGS AND PRECAUTIONS]
Adverse Reactions Occurring In More Than 1% of Patients
Skin: Pigmentation from pink to brownish-black in 75% to 100% of the patients within a few weeks of treatment; ichthyosis and dryness (8% to 28%); rash and pruritus (1% to 5%).Gastrointestinal: Abdominal and epigastric pain, diarrhoea, nausea, vomiting, gastrointestinal intolerance (40%-to-50%).
Ocular: Conjunctival and corneal pigmentation due to clofazimine crystal deposits; dryness; burning; itching; irritation.
Other: Discoloration of urine, faeces, sputum, sweat; elevated blood sugar; elevated erythrocyte sedimentation rate (ESR).
Adverse Reactions Occurring In Less Than 1% of Patients
Skin: Phototoxicity, erythroderma, acneiform eruptions, monilial cheilosis.Gastrointestinal: Bowel obstruction, gastrointestinal bleeding, anorexia, constipation, weight loss, hepatitis, jaundice, eosinophilic enteritis, enlarged liver.
Ocular: Diminished vision, maculopathy (bull’s eye retinopathy).
Nervous: Dizziness, drowsiness, fatigue, headache, giddiness, neuralgia, taste disorder.
Psychiatric: Depression and suicide secondary to skin discolouration.
Laboratory: Elevated levels of albumin, serum bilirubin, and aspartate aminotransferase (AST); eosinophilia; hypokalemia.
Other: Splenic infarction, thromboembolic,
anaemia, cystitis, bone pain, oedema, fever, lymphadenopathy, vascular pain.
DRUG INTERACTIONS
No Information ProvidedWARNINGS
Included as part of the PRECAUTIONS section.PRECAUTIONS
Abdominal Obstruction And Other Gastrointestinal Adverse Reactions
Clofazimine may accumulate in various organs as crystals, including the mesenteric lymph nodes and histiocytes at the lamina propria of the intestinal mucosa, spleen and liver. Deposition in the intestinal mucosa may lead to the intestinal obstruction that may necessitate exploratory laparotomy. Splenic infarction, gastrointestinal bleeding, and death have been reported. If a patient complains of pain in the abdomen, nausea, vomiting, or diarrhoea, initiate appropriate medical investigations and reduce the daily dose of Clofazimine, or increase the dosing interval or discontinue the drug. Doses of Clofazimine of more than 100 mg daily should be given for as short a period as possible (less than 3 months) and only under close medical supervision.QT prolongation
Cases of Torsades de Pointes with QT prolongation have been reported in patients receiving dosage regimens containing higher than 100 mg daily dose of Clofazimine or in combination with QT-prolonging medications. For QT prolongation and Torsades de Pointes cases, the patient must remain under medical surveillance. In all these patients, monitor electrocardiograms (ECGs) for QT prolongation and cardiac rhythm disturbances [see DOSAGE AND ADMINISTRATION].QT prolongation has also been reported in patients who were receiving Clofazimine with bedaquiline at the recommended dosage regimen for each drug. Monitor ECGs if Clofazimine is coadministered to patients receiving bedaquiline, and discontinue Clofazimine if the clinically significant ventricular arrhythmia is noted or if the QTcF interval is 500 ms or greater. If syncope occurs, obtain an ECG to detect QT prolongation.
Skin And Body Fluid Discoloration And Other Skin Reactions
Clofazimine causes orange-pink to brownish-black discolouration of the skin, as well as discolouration of the conjunctivae, tears, sweat, sputum, urine and faeces in 75-100% of patients. Advise patients that skin discolouration is likely to occur and that it may take several months or years to reverse after the conclusion of therapy.Other skin reactions associated with Clofazimine therapy include ichthyosis, dry skin and pruritus.
Psychological Effects Of Skin Discoloration
Skin discolouration due to Clofazimine therapy has been reported to result in depression and suicide. Advise patients regarding skin discolouration and monitor for depression or suicidal ideation during Clofazimine therapy.Nonclinical Toxicology
Carcinogenesis, Mutagenesis, And Impairment Of Fertility
Long-term carcinogenicity studies in animals have not been conducted with Clofazimine. Results of mutagenicity studies (Ames test) were negative. There is some evidence of clastogenic potential in mice.Impaired female fertility (reduced number of offspring and lower proportion of implantations) was observed in one study in rats receiving Clofazimine (from 9 weeks before mating until weaning) at 50 mg/kg/day, equivalent to about 2.4 times the maximum recommended clinical dose. No non-clinical data on male fertility are available.
Use In Specific Populations
Pregnancy
Risk Summary
The background risk of major birth defects and miscarriage for the indicated population is unknown; however, in the U.S. general population, the estimated background risk of major birth defects is 2-4% and of miscarriage is 15-20% of clinically recognized pregnancies.
Clinical Considerations
Fetal/Neonatal Adverse ReactionsThe skin of infants born to pregnant mothers who had received Clofazimine during pregnancy is pigmented at birth.
Limited data is available regarding the reversibility of discolouration. Based on previous observations, discolouration gradually faded over the first year.
Data
Human DataThere are no studies of Clofazimine use in pregnant women. Few cases of clofazimine use during pregnancy have been reported in the literature. These reports indicate that the skin of infants born to women who had received Clofazimine during pregnancy was deeply pigmented at birth. Clofazimine should be used during pregnancy only if the potential benefit justifies the risk to the fetus.
Animal Data
Embryofetal toxicity studies were conducted in rats, rabbits and
mice. In mice Clofazimine-induced embryotoxicity and fetotoxicity were
evident. Retardation of fetal skull ossification increased incidences of
abortions and stillbirths, and impaired neonatal survival was observed
following prenatal exposure to Clofazimine at 25 mg/kg, equivalent to
the 0.6 times maximum recommended human daily dose [MRHD] (200 mg),
based on body surface area comparisons. The skin and fatty tissue of
offspring became discoloured approximately 3 days after birth, which was
attributed to the presence of clofazimine in the maternal milk. No
developmental effects were observed in rat or rabbits orally
administered clofazimine during organogenesis at doses up to 50 mg/kg
and 15 mg/kg,(equivalent to about 2.4 and 1.5 times the MRHD of 200 mg
based on body surface area) respectively. These animal studies were
conducted according to the standards at the time of initial drug
approval (1986) and not under current regulatory standards.Lactation
Risk summary
The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Clofazimine and any potential adverse effects on the breastfed infant from Clofazimine or from the underlying maternal condition.
Females And Males Of Reproductive Potential
Pregnancy Testing
Sexually-active females of reproductive potential should have a pregnancy test prior to starting treatment with Clofazimine.Contraception
Animal studies have shown Clofazimine to be harmful to the developing fetus. Advise sexually active females of reproductive potential to use effective contraception (methods that result in less than 1 % pregnancy rates) when using Clofazimine during treatment and for at least 4 months after stopping treatment with Clofazimine.Advise males taking Clofazimine to use a condom during intercourse while on treatment and for at least 4 months after stopping treatment with Clofazimine.
Infertility
Impaired female fertility (reduced number of offspring and lower proportion of implantations) was observed in one study in rats receiving Clofazimine. There are no non-clinical data on male fertility.
Pediatric Use
Safety and effectiveness of Clofazimine in pediatric patients have not been established.Geriatric Use
Clinical studies of Clofazimine did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.Patients with HIV Co-infection
Response to treatment, including treatment of erythema nodosum leprosum reactions, is not altered in HIV-positive and immunocompromised leprosy patients. Dose adjustments of Clofazimine are not required in these patients.OVERDOSE
No specific data are available on the treatment of overdosage with Clofazimine. However, in case of overdose, the stomach should be emptied by inducing vomiting or by gastric lavage, and supportive symptomatic treatment should be employed.CONTRAINDICATIONS
Clofazimine is contraindicated in patients with known hypersensitivity to clofazimine or any of the excipients of Clofazimine.CLINICAL PHARMACOLOGY
Mechanism Of Action
Clofazimine is an antimycobacterial drug [see Microbiology].Pharmacokinetics
Absorption
Clofazimine has a variable absorption rate in leprosy patients, ranging from 45% to 62% after oral administration of Clofazimine. The average serum concentrations of clofazimine in leprosy patients treated with Clofazimine 100 mg and 300 mg daily were 0.7 mcg/mL and 1 mcg/mL, respectively.Time to reach peak plasma concentration (median Tmax) of clofazimine decreases from 12 hours to 8 hours under fed conditions relative to the fasted state.
Distribution
Clofazimine is highly lipophilic and tends to be deposited predominantly in fatty tissue and in cells of the reticuloendothelial system. It is taken up by macrophages throughout the body. In autopsies performed on leprosy patients who had received Clofazimine, clofazimine crystals were found predominantly in the mesenteric lymph nodes, adrenals, subcutaneous fat, liver, bile, gall bladder, spleen, small intestine, muscles, bones, and skin.Clofazimine is bound to alpha-and beta-lipoproteins in serum, particularly the beta-lipoproteins, and the binding was saturable at plasma concentrations of approximately 10 mcg/mL. Binding to gamma-globulin and albumin was negligible.
Metabolism
Three clofazimine metabolites were found in urine following repeated oral doses of Clofazimine. Information on the metabolism of clofazimine is limited.Elimination
After ingestion of a single 300 mg dose of Clofazimine, elimination of unchanged clofazimine and its metabolites in a 24-hour urine collection was negligible. Part of the ingested drug recovered from the faeces may represent excretion via the bile. A small amount is also eliminated in the sputum, sebum, and sweat. The elimination half-life of clofazimine following repeated oral doses of 50 or 100 mg Clofazimine in leprosy patients was highly variable with estimates ranging from 6.5 to 160 days. The overall mean half-life of clofazimine in these leprosy patients was approximately 25 days.Microbiology
Mechanism Of Action
Clofazimine exerts a slow bactericidal effect on Mycobacterium leprae (Hansen’s bacillus). Clofazimine inhibits mycobacterial growth and binds preferentially to mycobacterial DNA. Clofazimine also exerts anti-inflammatory properties in treating erythema nodosum leprosum reactions. However, its precise mechanisms of action are unknown.The mechanism of action for the antimycobacterial activity of clofazimine can be postulated through its membrane-directed activity including the bacterial respiratory chain and ion transporters. Intracellular redox cycling, involving oxidation of reduced clofazimine, leads to the generation of antimicrobial reactive oxygen species (ROS), superoxide hydrogen peroxide (H2O2). Secondly, the interaction of clofazimine with membrane phospholipids results in the generation of antimicrobial lysophospholipids, which promote membrane dysfunction, resulting in interference with K+ uptake. Both mechanisms result in interference with cellular energy metabolism by disrupting ATP production. Anti-inflammatory activity of clofazimine is primarily through inhibition of T lymphocyte activation and proliferation. Clofazimine may indirectly interfere with the proliferation of T cells by promoting the release of ROS and E-series prostaglandins (PGs), especially PGE2 from neutrophils and monocytes.
Measurement of the minimum inhibitory concentration (MIC) of clofazimine against leprosy bacilli in vitro is not yet feasible.
Cross-Resistance
Clofazimine does not show cross-resistance with dapsone or rifampin.PATIENT INFORMATION
- Inform patients to take Clofazimine with meals.
- Inform patients to report abdominal pain or other gastrointestinal symptoms, such as nausea or vomiting, to their healthcare provider.
- Inform patients that Clofazimine frequently causes a red to brownish-black discolouration of the skin as well as discolouration of the conjunctivae, tears, sweat, sputum, urine, and faeces. Advise patients that skin discolouration may take several months or years to resolve after the conclusion of therapy with Clofazimine.
- Inform patients that skin discolouration may result in psychological effects and advise them to report any symptoms of depression or suicidal ideation.
- Advise females of reproductive potential to use effective contraception while taking Clofazimine and for at least 4 months after stopping treatment with Clofazimine. It is also recommended that they have a pregnancy test prior to starting treatment with Clofazimine.
- Advise males taking LAMRENE to use a condom during intercourse while taking Clofazimine and for at least 4 months after stopping treatment.
- Inform patients of the importance of compliance with the prescribed drug regimen in order to prevent drug resistance. Irregularity in administration of medication and poor compliance can lead to a delayed and incomplete cure and could result in infecting other people. Poor compliance can result in disease progression and ultimately result in the development of disabilities and deformities. Whenever possible, ensure that non-compliant patients receive adequate assessment, health education and supervised treatment.
- Instruct patients on the recognition of signs and symptoms of inflammatory reactions and relapses during and following completion of treatment, and instruct them regarding the importance of immediately reporting the earliest manifestations of these signs to their healthcare provider.
Clofazamine is taken to treat leprosy (Hansen’s disease).
It is sometimes given with other medicines for leprosy. When clofazimine is used to treat `flare-ups’ of leprosy, it may be given with a cortisone-like medicine.
Clofazimine may also be used for other problems as determined by your doctor.Clofazamine is taken to treat leprosy (Hansen’s disease).
It is sometimes given with other medicines for leprosy. When clofazimine is used to treat `flare-ups’ of leprosy, it may be given with a cortisone-like medicine.Clofazimine may also be used for other problems as determined by your doctor.Clofazamine is taken to treat leprosy (Hansen’s disease).
Clofazimine
| Clofazimine | |||||
| Generics Name | |||||
Composition
|
Packing
|
Expiry
|
|||
| Clofazimine 50mg | 10 |
3 Yrs
|
|||
| Clofazimine 100mg | 10 |
3 Yrs
|
|||
Generic Manufacturing Facilities – Taj Pharmaceuticals (Manufacturing Possibilities)
Taj Pharmaceuticals is a pharmaceuticals company engaged in manufacturing of generic medicines, finished formulation (Branded), Active Pharmaceuticals Ingredients (Api) and Chemicals.
The Generic Manufacturing is to build innovative pharmaceuticals product and useful packaging, quality and manufacturing drugs according to the customised customer's specifications. We can customize one batch of Generic Medicine or an entire set of products in accordance to countries language and health regulations.
Taj Pharmaceuticals has well established WHO / GMP compliance manufacturing units. The company manufactures its brands and generics with 4600 generic medicine permissions in India.
Taj Pharmaceuticals Ltd. is a Pharmaceutical Generic manufacturer of Clofazimine and manufacturer of various pharmaceutical formulations in India. Taj Pharmaceuticals Ltd. provide different pharmaceutical brands and Generic Medicines.
The generic manufacturing strategies of New Drug (Clofazimine) and the product-process of Taj Pharmaceuticals Ltd. are compared and collaborated using data from global Pharmaceuticals manufacturing plants in the UK(Newcastle), US, Korea, Italy, Germany and Japan.
We are an eminent manufacturer, supplier and exporter of Clofazimine and various pharmaceuticals generics medicines in Tablets, capsules, Vial (injections), ampule, Strips and schedule packs etc.
Clofazimine and different pharmaceuticals Tablet & Capsule formulations are also available in different drug delivery forms. We also have large volume manufacturing facilities for these Products.
Clofazimine can be manufactured on order basis and also for brand registration in different countries. Our company meets all the required documents, DMF files, registration documents etc.
Clofazimine is manufactured and exported to all Middle East countries and the other continents like Europe, Thailand, Bangladesh, North America, South America, Russia, Newzeland and United Kingdom.
With over two decades of experience, we, Taj Pharmaceuticals Ltd., are one of the leading generic pharmaceutical companies. We believe that access to quality healthcare is a right, and not a privilege. Therefore, we endeavour to ensure the availability of world class, quality medicines at affordable prices across the globe.
We are committed to work towards a healthier and happier world. The company is an integrated; research based international pharmaceutical company, producing a wide range of quality, affordable generic (Clofazimine) medicines, trusted by health-care professionals and patients across geographies.
We offer you the highest quality new Generic medicines ie. Clofazimine, drugs and also with innovative packing at the lowest prices shipped to you from India. Browse our latest Pharmaceuticals and Generics possibilities and other pharmaceuticals possibilities…more...
Taj Pharmaceuticals is a pharmaceuticals company engaged in manufacturing of generic medicines, finished formulation (Branded), Active Pharmaceuticals Ingredients (Api) and Chemicals.
The Generic Manufacturing is to build innovative pharmaceuticals product and useful packaging, quality and manufacturing drugs according to the customised customer's specifications. We can customize one batch of Generic Medicine or an entire set of products in accordance to countries language and health regulations.
Taj Pharmaceuticals has well established WHO / GMP compliance manufacturing units. The company manufactures its brands and generics with 4600 generic medicine permissions in India.
Taj Pharmaceuticals Ltd. is a Pharmaceutical Generic manufacturer of Clofazimine and manufacturer of various pharmaceutical formulations in India. Taj Pharmaceuticals Ltd. provide different pharmaceutical brands and Generic Medicines.
The generic manufacturing strategies of New Drug (Clofazimine) and the product-process of Taj Pharmaceuticals Ltd. are compared and collaborated using data from global Pharmaceuticals manufacturing plants in the UK(Newcastle), US, Korea, Italy, Germany and Japan.
We are an eminent manufacturer, supplier and exporter of Clofazimine and various pharmaceuticals generics medicines in Tablets, capsules, Vial (injections), ampule, Strips and schedule packs etc.
Clofazimine and different pharmaceuticals Tablet & Capsule formulations are also available in different drug delivery forms. We also have large volume manufacturing facilities for these Products.
Clofazimine can be manufactured on order basis and also for brand registration in different countries. Our company meets all the required documents, DMF files, registration documents etc.
Clofazimine is manufactured and exported to all Middle East countries and the other continents like Europe, Thailand, Bangladesh, North America, South America, Russia, Newzeland and United Kingdom.
With over two decades of experience, we, Taj Pharmaceuticals Ltd., are one of the leading generic pharmaceutical companies. We believe that access to quality healthcare is a right, and not a privilege. Therefore, we endeavour to ensure the availability of world class, quality medicines at affordable prices across the globe.
We are committed to work towards a healthier and happier world. The company is an integrated; research based international pharmaceutical company, producing a wide range of quality, affordable generic (Clofazimine) medicines, trusted by health-care professionals and patients across geographies.
We offer you the highest quality new Generic medicines ie. Clofazimine, drugs and also with innovative packing at the lowest prices shipped to you from India. Browse our latest Pharmaceuticals and Generics possibilities and other pharmaceuticals possibilities…more...
Generic Manufacturer – Taj Pharmaceuticals
Our number one priority at Generic Manufacturing is to build innovative and useful packaging, quality and manufacturing drugs according to the customer's specifications. We can customize one batch of Generic Medicine or an entire set of products.
Taj Pharmaceuticals
Ltd. is a Pharmaceutical Generic manufacturer of Clofazimine and
manufacturer of various pharmaceutical formulations in India. Taj
Pharmaceuticals Ltd. provide different pharmaceutical brands and
Generic Medicines
The generic
manufacturing strategies of New Drug (Clofazimine) and the
product-process of Taj Pharmaceuticals Ltd. are compared and
collaborated using data from global Pharmaceuticals manufacturing
plants in the UK(Newcastle), US, Korea, Italy, Germany and Japan.
We are an eminent
manufacturer, supplier and exporter of Clofazimine and various
pharmaceuticals generics medicines in Tablets, capsules, Vial
(injections), ampule, Strips and schedule packs etc.
Clofazimine and
different pharma Tablet & Capsule formulations are also available in
different drug delivery forms. We also have large volume
manufacturing facilities for these Products.
With over two
decades of experience, we, Taj Pharmaceuticals Ltd., are one of the
leading generic pharmaceutical companies. We believe that access to
quality healthcare is a right, and not a privilege. Therefore, we
endeavor to ensure the availability of world class, quality
medicines at affordable prices across the globe.
We are committed to
work towards a healthier and happier world. The company is an
integrated, research based international pharmaceutical company,
producing a wide range of quality, affordable generic (Clofazimine)
medicines, trusted by health-care professionals and patients across
geographies.
We offer you the
highest quality new Generic medicines ie. Clofazimine, drugs and
also with innovative packing at the lowest prices shipped to you
from India. Browse our latest Pharmaceuticals and Generics
possibilities and other pharmaceuticals possibilities…more.
Clofazimine
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Comments
Post a Comment